HARP (Harpoon Therapeutics) יחס שווי שוק לשווי בספרים

Harpoon Therapeutics (HARP) has completed its autonomous expansion phase by merging its developments with the resources of a global pharma behemoth. The market's revaluation coefficient of balance sheet capital demonstrates the asset's current momentum, while 20.59 records a new level mark. Business stability relies on patent protection and patient survival data, with the primary growth catalyst remaining the implementation of innovations in lung cancer therapy.

Harpoon Therapeutics (HARP) specializes in developing innovative antibodies to combat solid tumors under the aegis of a global biopharma behemoth. This indicator is calculated as the quotient of the total market capitalization divided by the amount of equity. The metric reflects the market premium over net assets, revealing whether the business is overvalued or undervalued. The GURU.Markets toolkit allows users to track the integrity of asset write-downs through the historical market-to-book ratio. This is critical for assessing the real value of the issuer's scientific foundation.